PrecivityAD2 is a blood test that helps doctors check for Alzheimer's-related brain changes in adults age 40 and older with cognitive symptoms. For people with mild cognitive impairment, which means noticeable memory or thinking changes that do not prevent daily activity, the 2026 news means persistent midlife symptoms deserve a clinical evaluation that can now include blood-biomarker testing. The U.S.
Food and Drug Administration cleared the test on Aug. 20, 2026 for symptomatic adults, the first cleared test for patients as young as 40, according to the C2N Diagnostics announcement. That clearance does not make it a home screening test. It gives clinicians another tool during a full workup for mild cognitive impairment or dementia.
Medical information disclaimer: This article is for general educational purposes only and does not provide medical advice, diagnosis, or treatment. Always consult a physician or other qualified health professional about symptoms, medications, tests, or treatment decisions.
Table of Contents
- What does the test measure?
- Why does this matter before age 65?
- What are the limits?
- What can you do if you have MCI symptoms?
What does the test measure?
PrecivityAD2 uses high-resolution mass spectrometry to measure ratios involving amyloid-beta and p-tau217 in blood. It reports an amyloid pathology score that helps rule in or rule out Alzheimer's pathology, according to the C2N Diagnostics announcement. The score supports a clinician's judgment. It does not by itself diagnose Alzheimer's disease. The test is intended for people with mild cognitive impairment or dementia who are already being evaluated.
C2N estimates that group includes 19-20 million U.S. adults age 65 and older plus hundreds of thousands ages 45-65. A blood draw is often simpler for patients than brain PET imaging or spinal fluid testing. In research cited for primary care, adding the test to clinical assessment raised diagnostic accuracy from 65 percent to 93 percent, according to AJMC reporting. That gain matters because midlife forgetfulness is often first attributed to stress, depression, or workload. A biomarker result gives the clinician objective data to weigh.
Why does this matter before age 65?
Young-onset Alzheimer's means symptoms begin before age 65. It is often misdiagnosed and recognized late, after problems at work or with bills and planning become clear. Late recognition delays care planning, support services, and consideration of early-stage therapies. An October 2026 Finnish population study of early-onset disease found more psychiatric, neurologic, and health-care visits up to ten years before diagnosis, according to MedicalXpress reporting on the University of Oulu study.
The same study did not find excess classic cardiovascular risk factors. The pattern fits what patients report: years of appointments for mood, sleep, focus, or neurologic complaints before cognitive impairment is named. A cleared blood test for adults from age 40 gives younger symptomatic adults a clearer path to specialty referral. It does not explain every early symptom. It can shorten the period when treatable causes go unchecked and Alzheimer's pathology goes unassessed.
What are the limits?
PrecivityAD2 must be used with standard clinical workup by professionals experienced in cognitive impairment. The Alzheimer's Association summary states it is not standalone screening and not a definitive Alzheimer's diagnosis. A normal result still needs clinical interpretation. An abnormal result still needs staging, counseling, and follow-up testing decisions. Blood biomarkers do not replace history from the patient and family, cognitive testing, medication review, labs, and brain imaging when indicated.
Other conditions can impair memory, including sleep apnea, depression, thyroid disease, vitamin deficiency, and medication effects. The value of the blood score depends on pre-test likelihood, sample quality, and the clinician's experience. Access, coverage, and follow-up options also vary by clinic and region. A positive pathology score can affect employment, driving, insurance planning, and family decisions. Discuss those implications before testing and plan who will receive results.
What can you do if you have MCI symptoms?
Adults ages 40 to 64 with persistent memory or thinking problems can ask a clinician about blood-biomarker evaluation as part of a cognitive workup. The evaluation uses one blood draw and may reduce need for PET imaging or spinal tap, according to the Alzheimer's Association summary.
Ask whether your clinic offers the cleared test and what follow-up it would change. Bring that written history to the appointment and ask for a clear next-step date.
- Note persistent changes for two to three months, with dates and work impact
- Bring a family member who has observed the changes
- List sleep problems, mood changes, medications, alcohol use, and head injury
- Ask what else will be checked, who interprets the blood result, and when to return
You Might Also Like
- The Third FDA-Cleared Alzheimer’s Blood Biomarker Test in 2026: What People With Mild Cognitive Impairment Should Know About the News
- Vitamin Supplements in the 2026 WHO Dementia Guideline: What Is Established and What Is Still Being Studied for People With Mild Cognitive Impairment
- Healthy Diets in the 2026 WHO Dementia Guideline: What Is Established and What Is Still Being Studied for People With Mild Cognitive Impairment
